deltatrials
Completed PHASE3 INTERVENTIONAL 3-arm NCT03197922

Treatment of Encopresis in Children With Autism Spectrum Disorders

A Multidisciplinary Approach to the Treatment of Encopresis in Children With Autism Spectrum Disorders

Sponsor: Emory University

Conditions Autism Spectrum Disorder Encopresis
Interventions Glycerin Suppository MIE Treatment Treatment as Usual (TAU)
Updated 16 times since 2017 Last updated: Jan 5, 2024 Started: Oct 25, 2017 Primary completion: Nov 17, 2022 Completion: Nov 17, 2022
This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

This PHASE3 trial investigates Autism Spectrum Disorder and Encopresis and is currently completed. Emory University leads this study, which shows 16 recorded versions since 2017 — indicating substantial longitudinal coverage. This study adds to the longitudinal dataset for psychiatric treatment development.

Status Flow

~Jul 2017 – ~Dec 2017 · 5 months · monthly snapshot~Dec 2017 – ~Jun 2018 · 6 months · monthly snapshot~Jun 2018 – ~Jan 2019 · 7 months · monthly snapshot~Jan 2019 – ~Jan 2020 · 12 months · monthly snapshot~Jan 2020 – ~Mar 2020 · 2 months · monthly snapshot~Mar 2020 – ~May 2020 · 2 months · monthly snapshot~May 2020 – ~Jan 2021 · 8 months · monthly snapshot~Jan 2021 – ~Jan 2022 · 12 months · monthly snapshot~Jan 2022 – ~Sep 2022 · 8 months · monthly snapshot~Sep 2022 – ~Mar 2023 · 6 months · monthly snapshot~Mar 2023 – ~Jun 2023 · 3 months · monthly snapshot~Jun 2023 – ~Jan 2024 · 7 months · monthly snapshot~Jan 2024 – ~Feb 2024 · 31 days · monthly snapshot~Feb 2024 – ~Jul 2024 · 5 months · monthly snapshot~Jul 2024 – ~Sep 2024 · 2 months · monthly snapshot~Sep 2024 – present · 22 months · monthly snapshot

Change History

16 versions recorded

  1. Sep 2024 — Present [monthly]

    Completed PHASE3

  2. Jul 2024 — Sep 2024 [monthly]

    Completed PHASE3

  3. Feb 2024 — Jul 2024 [monthly]

    Completed PHASE3

  4. Jan 2024 — Feb 2024 [monthly]

    Completed PHASE3

  5. Jun 2023 — Jan 2024 [monthly]

    Completed PHASE3

▶ Show 11 earlier versions

  1. Mar 2023 — Jun 2023 [monthly]

    Completed PHASE3

    Status: Active Not Recruiting → Completed

  2. Sep 2022 — Mar 2023 [monthly]

    Active Not Recruiting PHASE3

    Status: Recruiting → Active Not Recruiting

  3. Jan 2022 — Sep 2022 [monthly]

    Recruiting PHASE3

  4. Jan 2021 — Jan 2022 [monthly]

    Recruiting PHASE3

    Status: Suspended → Recruiting

  5. May 2020 — Jan 2021 [monthly]

    Suspended PHASE3

    Status: Recruiting → Suspended

  6. Mar 2020 — May 2020 [monthly]

    Recruiting PHASE3

  7. Jan 2020 — Mar 2020 [monthly]

    Recruiting PHASE3

  8. Jan 2019 — Jan 2020 [monthly]

    Recruiting PHASE3

  9. Jun 2018 — Jan 2019 [monthly]

    Recruiting PHASE3

  10. Dec 2017 — Jun 2018 [monthly]

    Recruiting PHASE3

    Status: Not Yet Recruiting → Recruiting

  11. Jul 2017 — Dec 2017 [monthly]

    Not Yet Recruiting PHASE3

    First recorded

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:
  • Emory University
  • United States Department of Defense
Data source: Emory University

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations